Research and Reports
Submissions Highlighting our Community Needs
Multiple Sclerosis NZ makes submissions on policies and bills which will have a significant impact on the MS community and MS service. We invite you to read some of our latest submissions:
Recent Submissions by MSNZ
Research and Reports
We proudly stand as an evidence-based organisation investing in reports and research which progresses our advocacy mission. These publications we’ve commissioned have helped to further the positive change we’re making together with our community and partners:
Societal Costs of MS
The 2024 Milne Report, commissioned by Multiple Sclerosis NZ, provided evidence to recommend Pharmac should base funding decisions not just on the cost of a medicine, but on the wider fiscal impact of funding it, or not, on New Zealand society as a whole.
The report, ‘The Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand from Healthcare and Societal Perspectives’ was undertaken by health economist Dr Richard Milne and colleagues in New Zealand, Tasmania and Singapore, as an economic case study evaluation of ocrelizumab for PPMS.
Economic Burden of MS
In 2022 the New Zealand Institute of Economic Research released the 2021 Economic Burden of MS Report, commissioned by the Multiple Sclerosis NZ. The report showed that earlier intervention of Multiple Sclerosis will not only save New Zealand’s health system millions of dollars per year, it will also contribute millions back into the economy through individual income related earnings.
aHCST and Sativex
In 2017, MSNZ commissioned researcher Kerry Walker to review the evidence surrounding the use of aHSCT and Sativex, cannabis-based medicine, for people with MS.